Buscar
Mostrando ítems 1-5 de 5
Artículo
Combined treatment of graft versus host disease using donor regulatory T cells and ruxolitinib
(Nature Publishing Group, 2022)
Donor derived regulatory T lymphocytes and the JAK1/2 kinase inhibitor ruxolitinib are currently being evaluated as therapeutic options in the treatment of chronic graft versus host disease (cGvHD). In this work, we ...
Artículo
Editorial: Regulatory T cells in graft versus host disease
(Frontiers Media, 2023-02-20)
Regulatory T cells (Tregs) are modulators of the immune system that play a key role in maintaining self-tolerance. Treg were initially identified by Sakaguchi as CD4+CD25+ T cells that have the ability to suppress autoimmune ...
Artículo
Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
(Nature Publishing Group, 2021)
Multiple myeloma (MM) is incurable, so there is a significant unmet need for effective therapy for patients with relapsed or refractory disease. This situation has not changed despite the recent approval of the anti-CD38 ...
Artículo
Delayed administration of ixazomib modifies the immune response and prevents chronic graft-versus-host disease
(Nature Publishing Group, 2021-09-23)
In this study, we aimed to modify the immune response in the long term after allogeneic bone marrow transplantation (allo-BMT) by using the proteasome inhibitor ixazomib (IXZ) at the late stages of the post-transplant ...
Artículo
Effect of Vitamin D on Graft-versus-Host Disease
(MDPI, 2022)
The different cell subsets of the immune system express the vitamin D receptor (VDR). Through the VDR, vitamin D exerts different functions that influence immune responses, as previously shown in different preclinical ...